Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2021-04-23 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT AS AT 31.03.2021' and contains comprehensive financial data, including consolidated interim financial statements, explanatory notes, and a report of the statutory auditors. It covers a period shorter than a full fiscal year (Q1), fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-04-23 German
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share
AGM Information Classification · 99% confidence The document text explicitly mentions 'Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend'. It details the outcomes of the Annual General Meeting (AGM), including the approval of the dividend and the re-election of board members. This content directly aligns with the definition of 'AGM Information' (Code: AGM-R). Although it mentions dividend approval, the primary focus and context are the meeting results, not just the dividend announcement itself (DIV).
2021-03-18 English
BB Biotech AG publishes its 2020 annual report
Report Publication Announcement Classification · 99% confidence The document is a news release dated February 19, 2021, titled "BB Biotech AG publishes its 2020 annual report." It explicitly states that the company published its annual report for fiscal year 2020 and provides a link to access it. The document itself contains summary financial highlights (net gain, total share return) but its primary function, based on its structure and short length (4259 chars), is to announce the availability of the full report, rather than being the comprehensive report itself. According to Rule 2 (The 'MENU VS MEAL' Rule), when a short document announces the publication of a full report, it should be classified as a Report Publication Announcement (RPA). Although it mentions the 'annual report', the text is an announcement of that report's release.
2021-02-19 English
Jahresfinanzbericht 2020
Annual Report Classification · 100% confidence The document is a comprehensive 'Geschäftsbericht' (Annual Report) for BB Biotech AG for the fiscal year 2020. It contains a detailed table of contents, consolidated financial statements (balance sheet, income statement, cash flow), audit reports, corporate governance information, remuneration reports, and management commentary. It is clearly the full annual report rather than an announcement or a summary. Q4 2020
2021-02-19 German
Initiation research from QuotedData
Regulatory Filings Classification · 98% confidence The document is very short (3510 characters) and explicitly states it is distributing 'research' from an external party (QuotedData) via the RNS system. It contains a link to the full research report and mentions that the information is provided by 'Reach, the non-regulatory press release distribution service of RNS'. This structure—announcing the availability of external research rather than being the research itself or a mandatory regulatory filing like a 10-K or ER—strongly indicates a Report Publication Announcement (RPA) or, given the non-regulatory nature emphasized, a general Regulatory Filing (RNS) fallback. Since the document's primary function is to announce the publication of third-party research, RPA is the most specific fit, although RNS is also plausible as a general announcement mechanism. Given the context of announcing a specific piece of external research, RPA is chosen over the general RNS fallback.
2021-02-11 English
BB Biotech AG closes the 2020 fiscal year with a profit
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated January 22, 2021, titled 'BB Biotech AG closes the 2020 fiscal year with a profit'. It discloses preliminary, unaudited consolidated figures for the fiscal year 2020, reporting a profit of CHF 691 million. Crucially, it states that the 'complete annual report will be published on February 19, 2021.' Since this document is a short announcement providing key highlights (profit figures) and explicitly defers the release of the full annual report, it fits the definition of an Earnings Release (ER). It is not the full 10-K, nor is it a general regulatory filing (RNS) or a report publication announcement (RPA) since it contains the actual preliminary results, not just the notice of publication. FY 2020
2021-01-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.